Abstract
The AMP-activated protein kinase (AMPK) system is a regulator of energy balance at both the cellular and whole-body levels that, once activated by low energy status, effects a switch from ATP-consuming anabolic pathways to ATP-producing catabolic pathways. It now appears to be the major target for two existing classes of drug used to treat type 2 diabetes, i.e., the biguanides and thiazolidinediones. However, in both cases these activate AMPK indirectly, and an interesting question concerns whether a drug that directly activated AMPK would retain the therapeutic benefits of the existing drugs while eliminating unwanted side effects. AMPK activators also now have potential as anticancer drugs.
| Original language | English |
|---|---|
| Pages (from-to) | 185-210 |
| Number of pages | 26 |
| Journal | Annual Review of Pharmacology and Toxicology |
| Volume | 47 |
| DOIs | |
| Publication status | Published - Feb 2007 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- AMP-Activated Protein Kinases
- Antineoplastic Agents
- Biguanides
- Diabetes Mellitus, Type 2
- Drug Delivery Systems
- Humans
- Multienzyme Complexes
- Protein-Serine-Threonine Kinases
- Thiazolidinediones
Fingerprint
Dive into the research topics of 'AMP-activated protein kinase as a drug target'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver